Enliven Therapeutics (NASDAQ:ELVN) Shares Up 5.6%

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose 5.6% on Tuesday . The stock traded as high as $24.68 and last traded at $24.68. Approximately 21,677 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 269,321 shares. The stock had previously closed at $23.38.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Robert W. Baird started coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price on the stock. Mizuho initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Enliven Therapeutics Price Performance

The company has a 50 day moving average price of $22.53 and a 200 day moving average price of $19.02. The firm has a market cap of $1.18 billion, a PE ratio of -12.96 and a beta of 1.11.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total value of $278,160.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rishi Gupta sold 1,033,300 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $22.14, for a total transaction of $22,877,262.00. Following the sale, the director now owns 254,814 shares of the company’s stock, valued at $5,641,581.96. The disclosure for this sale can be found here. Insiders have sold 1,142,148 shares of company stock valued at $25,390,954 over the last quarter. Company insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at approximately $2,020,000. Blackstone Inc. purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $443,000. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $167,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Enliven Therapeutics in the 4th quarter valued at approximately $66,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.